Study S002566

An Open-Label, Multicenter Study to Evaluate 52-Week Long-Term Safety, Tolerability and Efficacy of Tofogliflozin With Glucagon-like Peptide-1(GLP-1) Analogue Treatment In Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02537834
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 65
Start: 2015-08
Primary completion: 2017-07
Lead sponsor: Kowa Company, Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Tofogliflozin; DRUG:GLP-1 analogue
Results posted: FALSE
Secondary identifiers: OTHER:TOFOGL07279

Registered primary outcomes

Safety and Tolerability Assessed by Adverse Event and Adverse Drug Reaction [baseline and Week 52]
Change from Baseline in HbA1c at 52 weeks [Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010008	Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. Terauchi Y, Journal of diabetes investigation	2019	Other trial	PMID 31033218 DOI	registry reference RESULT:31033218